PropertyValue
nif:beginIndex
  • 0 (xsd:integer)
nif:broaderContext
nif:endIndex
  • 189 (xsd:integer)
nif:isString
  • Aplaviroc was developed as a small molecule CCR5 antagonist to block HIV-1 entry but GlaxoSmithKline halted development in a phase II trial due to strong evidence of hepatic toxicity [133].
rdf:type